Literature DB >> 14663032

A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis.

.   

Abstract

OBJECTIVE: To assess the reliability of strength testing techniques among centers investigating patients with amyotrophic lateral sclerosis.
METHODS: The authors compared test reliability in manual muscle testing (MMT) and maximal voluntary isometric contraction (MVIC) scores among institutions and test validity by comparing change over time between MMT and MVIC. The authors examined 63 subjects at 3-month intervals for 12 months. At enrollment and at 6 months, two physical therapists each examined the subjects twice. MMT scores were calculated as modifications of the Medical Research Council scale. MVIC scores were generated as standardized megascores. Intraclass correlation coefficients and coefficients of variation compared reproducibility, and Pearson correlation coefficients compared change over time. The power of each measure to detect disease progression over time was assessed by estimating coefficients of variation for the average change.
RESULTS: Reproducibility between MVIC and MMT was equivalent. Sensitivity to detect progressive weakness and power to detect this change, however, favored MMT, an effect largely accounted for by the number of muscles sampled.
CONCLUSIONS: In multicentered trials, uniformly trained physical therapists reproducibly and accurately measure strength by both MMT and MVIC. The authors found MMT to be the preferred measure of global strength because of its better Pearson correlation coefficients, essentially equivalent reproducibility, and more favorable coefficient of variation.

Entities:  

Mesh:

Year:  2003        PMID: 14663032     DOI: 10.1212/01.wnl.0000095961.66830.03

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  A narrative review of manual muscle testing and implications for muscle testing research.

Authors:  Katharine M Conable; Anthony L Rosner
Journal:  J Chiropr Med       Date:  2011-08-09

2.  Progression in ALS is not linear but is curvilinear.

Authors:  Paul H Gordon; Bin Cheng; Francois Salachas; Pierre-Francois Pradat; Gaelle Bruneteau; Philippe Corcia; Lucette Lacomblez; Vincent Meininger
Journal:  J Neurol       Date:  2010-06-08       Impact factor: 4.849

Review 3.  Measures and markers in amyotrophic lateral sclerosis.

Authors:  Merit Cudkowicz; Muhammad Qureshi; Jeremy Shefner
Journal:  NeuroRx       Date:  2004-04

4.  Association between depression and survival in Chinese amyotrophic lateral sclerosis patients.

Authors:  Qianqian Wei; Zhenzhen Zheng; Xiaoyan Guo; Ruwei Ou; Xueping Chen; Rui Huang; Jing Yang; Huifang Shang
Journal:  Neurol Sci       Date:  2016-01-13       Impact factor: 3.307

Review 5.  Clinical Measures of Disease Progression in Amyotrophic Lateral Sclerosis.

Authors:  Seward B Rutkove
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

6.  Intraexaminer comparison of applied kinesiology manual muscle testing of varying durations: a pilot study.

Authors:  Katharine M Conable
Journal:  J Chiropr Med       Date:  2010-03

Review 7.  Strength Testing in Motor Neuron Diseases.

Authors:  Jeremy M Shefner
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 8.  Assessment of Motor Units in Neuromuscular Disease.

Authors:  Robert D Henderson; Pamela A McCombe
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

9.  A natural history study of late onset spinal muscular atrophy types 3b and 4.

Authors:  S Piepers; L H van den Berg; F Brugman; H Scheffer; M Ruiterkamp-Versteeg; B G van Engelen; C G Faber; M de Visser; W-L van der Pol; J H J Wokke
Journal:  J Neurol       Date:  2008-06-30       Impact factor: 4.849

10.  Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy.

Authors:  Jeffrey M Statland; Michael P McDermott; Chad Heatwole; William B Martens; Shree Pandya; E L van der Kooi; John T Kissel; Kathryn R Wagner; Rabi Tawil
Journal:  Neuromuscul Disord       Date:  2013-02-11       Impact factor: 4.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.